[Federal Register: July 14, 2004 (Volume 69, Number 134)]
[Notices]
[Page 42178-42183]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr14jy04-88]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Immediate Relief To Decrease Unsafe Injections in Selected
Countries in Africa and the Caribbean Under the President's Emergency
Plan for AIDS Relief
Announcement Type: New.
Funding Opportunity Number: 04212.
Catalog of Federal Domestic Assistance Number: 93.943.
Key Dates:
Application Deadline: August 13, 2004.
Executive Summary: President Bush's Emergency Plan for AIDS Relief
has called for immediate action to turn the tide of HIV/AIDS in Africa
and the Caribbean. An important aspect of the President's bold vision
is to prevent at least seven million HIV infections. This funding
opportunity responds to the President's call for rapid, accountable,
and sustainable action. An important aspect of the President's
Emergency Plan for AIDS Relief (PEPFAR) is the providing of assistance
to ensure the elimination of unsafe medical injections and other
related unsafe medical practices, including occupational exposure to
blood. The focus of this announcement is seven countries in Africa and
the Caribbean heavily affected by HIV/AIDS: Botswana, C[ocirc]te
d'Ivoire, Haiti, Kenya, Rwanda, South Africa, and Tanzania.
Transmission of HIV and hepatitis in the health care setting can
occur through unsafe injections and other unsafe medical practices,
including occupational exposure to blood. The persons most at risk of
infection through unsafe injections are the injection recipients,
health care workers through contaminated needles and syringes, and the
wider community through exposure to contaminated sharps waste.
Estimates of the global burden of disease from unsafe injections
suggests that, in the year 2000, unsafe injections around the world
accounted for five percent of HIV infections, 32 percent of hepatitis B
virus infections, 40 percent of hepatitis C virus infections, 28
percent of liver cancers, and 24 percent of cirrhosis cases (World
Health Organization (WHO), 2003). While such estimates have
limitations, the data suggests that injection overuse and unsafe
injection practices contribute towards contaminated, and often
unnecessary, injections in the formal and informal health sector, and
therefore constituting a significant mode of transmission for HIV and
hepatitis. Concern about the negative outcomes of unsafe injections,
including transmission of blood-borne pathogens, abscess formation,
etc., has focused attention on scaling up interventions to stop the
inappropriate and unsafe use of injection equipment.
This announcement provides funding to implement a National
Injection Safety Plan in each of the seven countries, and expects
demonstrable, measurable results within the first year of the award. An
additional intent is to develop sustained indigenous capacity to
continue these programs after the project ends.
Measurable outcomes of this program will be in alignment with the
following performance goal for President Bush's Emergency Plan for AIDS
Relief (PEPFAR): Prevent seven million HIV infections in 15 focus
countries heavily afflicted by AIDS.
This initiative is a coordinated effort led by the Office of the
Global AIDS Coordinator at the Department of State and involves various
U.S. Federal Government agencies including the Department of State,
Department of Health and Human Services (HHS), Department of Defense,
the U.S. Agency for International Development, and the Peace Corps.
I. Funding Opportunity Description
Authority: This program is authorized under Sections 301(a) and
307 of the Public Health Service Act [42 U.S.C. Sections 241 (a) and
242l], as amended, and under Public Law 108-25 (United States
Leadership Against HIV/AIDS, Tuberculosis and Malaria Act of 2003)
[22 U.S.C. 7601].
Purpose: This announcement is intended to fund the rapid
implementation of a safe-injection program that covers the entire
population of each country, using each country's National Injection
Safety Plan. The focus of this announcement is seven countries in
Africa and the Caribbean heavily affected by HIV/AIDS: Botswana,
C[ocirc]te d'Ivoire, Haiti, Kenya, Rwanda, South Africa, and Tanzania.
We expect demonstrable, measurable results within the first year of the
President's Emergency Plan for AIDS Relief (PEPFAR). The implementation
of these National Injection Safety Plans includes management,
operations, and monitoring activities. The awardee will work to
coordinate activities with the U.S. Government Mission, the Ministry of
Health (MOH), and non-governmental organizations (NGOs), as
appropriate, in each country.
All applicants should propose and budget for activities in all
seven countries. The final determination of country assignment and
funding will be determined at the time of award.
This funding announcement is intended to build on work recently
performed during the initial rapid implementation of safe-injection
activities under PEPFAR. The principal tasks of that rapid
implementation phase were as follows:
1. Perform an initial assessment of the current injection practices
within each country.
2. Develop a National Injection Safety Plan for the safe and
appropriate use of injections.
3. Design and field-test a project to enhance injection safety in
selected area(s) of each country that would address improving provider
skills, improve procurement and management of safe injection equipment
and supplies, increase managers' awareness and skills, and advocate for
reducing demand for injections and knowledge about injection safety
among the general public.
4. Develop and implement an advocacy strategy for wider public
understanding and support for the development of the National Injection
Safety Plan.
Measurable outcomes of the program will be in alignment with the
priorities of PEPFAR, a five-year initiative to turn the tide in
combating the global HIV/AIDS pandemic. The PEPFAR is intended to
address the goal of
[[Page 42179]]
preventing seven million new infections (60 percent of the projected
new infections in the target countries). By addressing injection
safety, PEPFAR can help to reduce the spread of HIV and other
infectious diseases and reduce the fear of infection among health care
workers, thereby lessening stigma among health care workers and
discrimination against people living with HIV/AIDS.
Activities: Awardee activities for this program are as follows:
Using each country's National Injection Safety Plan to be provided by
HHS/CDC, the awardee(s) will expand the piloted activities to implement
an injection-safety program that covers the total population of each
country. The awardee will implement a program that aims to improve
injection practices through the following components: (a) Training,
support, and capacity-building of health care providers, as well as
program and facility managers; (b) improving logistics supply and
distribution systems that ensure availability of safe injection
equipment; (c) reducing the frequency of unnecessary injections through
advocacy and behavior change; and (d) management of sharps waste.
1. Training, Support, and Capacity
Train and educate health care workers in safer medical
practices, including safe injection practices, universal precautions,
selection of appropriate waste-management options, and decreasing
unnecessary medications, particularly injections.
Develop and/or update institutional service-delivery
policies, standards, guidelines, job descriptions, monitoring tools,
etc., to reflect management practices in safe injections and in the
waste management of sharps waste (in accordance with national or
international standards).
Assist and train health care workers and logisticians in
safe-injection commodity forecasting, financing, procurement,
logistics, and supply management to ensure that both sterile, single-
use injection devices for injection and reconstitution and safety boxes
are available in health care facilities in sufficient quantities for
the number of injections administered.
Advise and assist program managers and facility
administrators to direct, supervise and monitor activities to improve
injection safety within their areas.
Develop a mechanism to review progress and lessons learned
between the National Injection Safety Plan group and personnel from the
pilot project.
2. Equipment, Supplies, and Commodity Management
Procure appropriate commodities for safe injection
practices and ensure that all health care facilities have sufficient
quantities of all commodities, including single-use injection
equipment, gloves, diluent, soap, and safety boxes, preferably using
existing distribution systems, when appropriate.
Develop and strengthen existing systems for reliable
commodity management, including selection, forecasting, procurement,
and distribution, of injection equipment matched with needs for
injectable medications and safety boxes in sufficient quantities for
the number of injections administered.
Ensure ``bundling'' of injectable vaccines, injectable
contraceptives, and tuberculosis medicines in donor-supported programs
with single-use needles and syringes that include reuse-prevention
features and safety boxes.
To decrease unnecessary injections, ensure oral
formulations of commonly used medications are available at the health
facilities. This might require revision of the essential drug list.
Ensure inclusion of injection equipment on essential drug
lists on a facility and/or national level.
3. Reducing Unnecessary Injections Through Advocacy and Behavior Change
Using each country's National Injection Safety Plan, the
awardee(s) will attempt to increase public support for injection safety
among the main target audiences, which include: program managers,
health facility administrators, professional associations, health
workers, pharmacies, training institutions including medical schools,
and the general public.
The awardee will work with non-governmental organizations
NGOs to integrate community-based activities to decrease the use of
unsafe injections and increase knowledge of injection safety.
4. Sharps Waste Management
Develop and strengthen systems to support proper disposal
of sharps at the level of this intervention. (The awardee would not
directly support capital costs for waste management. The awardee's role
would be limited to technical assistance in assessment, planning and
leveraging support from other external agencies for items such as
incinerators.) This should be done in accordance with national policies
for safe management of health care waste, if such a policy exists. If
such a policy does not exist, these activities should be done in
accordance with international standards (http://www.injectionsafety.org
and the SIGN Injection Safety Toolkit).
Forecast and provide sufficient quantities of puncture-
proof sharps containers (e.g. safety boxes) and related materials, such
as kerosene, matches for burning, etc., to meet the disposal needs of
injection equipment across the curative, immunization, and
contraceptive sectors within the institution. In a cooperative
agreement, HHS/CDC staff is substantially involved in the program
activities, above and beyond routine grant monitoring. HHS/CDC will
work under the guidance and supervision of the Office of the Global
AIDS Coordinator at the Department of State.
HHS/CDC activities for this program are as follows:
Provide scientific and technical assistance in refining
the operational plan.
Provide ongoing technical assistance in addressing
problems encountered in implementing your plan.
Assist in assessing program operations and in evaluating
overall effectiveness of your program.
Staff in both headquarters (HHS/CDC Atlanta, HHS/CDC in
country, and the HHS Office of Global Health Affairs in Washington) and
in the designated countries will assure that other related U.S.
Government (USG) activities are well coordinated with national programs
in each country.
II. Award Information
Type of Award: Cooperative Agreement. HHS/CDC involvement in this
program is listed in the Activities Section above.
Fiscal Year Funds: FY 2004.
Approximate Total Funding: $7,000,000.
Approximate Number of Awards: Two.
Approximate Average Award: $3,500,000 (This amount is for the first
12-month budget period, and includes direct costs).
Floor of Award Range: None.
Ceiling of Award Range: $7,000,000.
Anticipated Award Date: September 1, 2004.
Budget Period Length: 12 months.
Project Period Length: Five years.
Throughout the project period, HHS/CDC's commitment to continuation
of awards will be conditioned on the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required
reports), and the determination that continued funding is in the best
interest of the Federal Government.
[[Page 42180]]
III. Eligibility Information
III.1. Eligible Applicants
Applications may be submitted by public and private non-profit and
for-profit organizations may submit applications, such as:
Public non-profit organizations;
Private non-profit organizations;
For-profit organizations;
Universities; and
Faith-based organizations.
III.2. Cost Sharing or Matching
Matching funds are not required for this program.
III.3. Other
If you request a funding amount greater than the ceiling of the
award range, your application will be considered non-responsive and
will not be entered into the review process. You will be notified that
your application did not meet the submission requirements.
If your application is incomplete or non-responsive to the
requirements listed in this section, it will not be entered into the
review process. You will be notified that your application did not meet
submission requirements.
Note: Title 2 of the United States Code Section 1611 states that
an organization described in Section 501(c)(4) of the Internal
Revenue Code that engages in lobbying activities is not eligible to
receive Federal funds constituting an award, grant, or loan.
IV. Application and Submission Information
IV.1. Address To Request Application Package
To apply for this funding opportunity use application form PHS
5161. Application forms and instructions are available on the HHS/CDC
Web site, at the following Internet address: http://www.cdc.gov/od/pgo/forminfo.htm
.
If you do not have access to the Internet, or if you have
difficulty accessing the forms on-line, you may contact the HHS/CDC
Procurement and Grants Office Technical Information Management Section
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to
you.
IV.2. Content and Form of Submission
Application: You must include a project narrative with your
application forms. You must submit a narrative in the following format:
Maximum number of pages: 30 (Note: Appendices and budget
narrative are not included in the page total). If your narrative
exceeds the page limit, only the first pages, which are within the page
limit, will be reviewed.
Font size: 12-point unreduced
Double-spaced
Paper size: 8.5 by 11 inches
Page margin size: One inch
Printed only on one side of page
Held together only by rubber bands or metal clips; not
bound in any other way.
Your narrative proposal should address activities to be conducted
over the entire project period. Proposals should detail the
implementation of the methodologies put forward in the program
description, showing the phasing or dates by which planned activities
would be carried out. The implementation plan shall include the
following:
Description of the need for National Injection Safety
Plans in the seven countries and the anticipated outcome on HIV
prevention.
Description of the rationale and technical approach for
expanding the use of proven best practices in injection safety in the
following countries: Botswana, C[ocirc]te d'Ivoire, Haiti, Kenya,
Rwanda, South Africa, and Tanzania.
Description of all planned activities in the first 12
months, including:
a. Sequence of tasks and location for intervention.
b. Timeframes for implementing each activity.
c. Involvement of alliances/partners/twinning.
d. Procurement and distribution plan, including estimated equipment
needs and plans for use of existing country mechanisms.
e. Sustainability plan.
Management Plan
a. Proposed lines of responsibility, authority, and communication
through which tasks will be managed.
b. Procedure to ensure quality control and cost control.
Organizational Structure and Staffing Plan, including:
a. Key personnel plan.
b. Other long and short-term staff required for implementing each
activity.
c. Demonstrated capabilities, specific local experiences,
education, and qualifications for each member of the key personnel
plan.
d. List of alternates for key personnel plan.
e. Subcontractor staffing plans.
f. Plan for proposed project team to interface with the applicant's
corporate structure, possible sub-contractors, and HHS/CDC's management
structure.
Monitoring and Evaluation Plan, showing how:
a. Outcomes will be measured.
b. Outcomes will contribute to results.
The applicants shall provide information regarding their
past experience in working with other organizations on similar types of
projects.
Applicants may include additional information in the application
appendices. The appendices will not be counted toward the narrative
page limit. This additional information includes the following:
Curriculum Vitas or Resumes;
Organizational Charts; and
Letters of Support, etc.
You are required to have a Dun and Bradstreet Data Universal
Numbering System (DUNS) number to apply for a grant or cooperative
agreement from the Federal government. The DUNS number is a nine-digit
identification number, which uniquely identifies business entities.
Obtaining a DUNS number is easy and there is no charge. To obtain a
DUNS number, access http://www.dunandbradstreet.com or call 1-866-705-5711.
For more information, see the HHS/CDC Web site at: http://www.cdc.gov/od/pgo/funding/pubcommt.htm
.
If your application form does not have a DUNS number field, please
write your DUNS number at the top of the first page of your
application, and/or include your DUNS number in your application cover
letter.
Additional requirements that may require you to submit additional
documentation with your application are listed in section ``VI.2.
Administrative and National Policy Requirements.''
IV.3. Submission Dates and Times
Application Deadline Date: August 13, 2004.
Explanation of Deadlines: Applications must be received in the HHS/
CDC Procurement and Grants Office by 4 p.m. eastern time on the
deadline date. If you send your application by the United States Postal
Service or commercial delivery service, you must ensure that the
carrier will be able to guarantee delivery of the application by the
closing date and time. If HHS/CDC receives your application after
closing because of: (1) Carrier error, when the carrier accepted the
package with a guarantee for delivery by the closing date and time, or
(2) significant weather delays or natural disasters, you will be given
the opportunity to submit documentation of the carrier's guarantee. If
the documentation verifies a carrier problem, HHS/CDC will consider the
application as having been received by the deadline.
This announcement is the definitive guide on application submission
address and deadline. It supersedes
[[Page 42181]]
information provided in the application instructions. If your
application does not meet the deadline above, it will not be eligible
for review, and will be discarded. You will be notified that your
application did not meet the submission requirements.
HHS/CDC will not notify you upon receipt of your application. If
you have a question about the receipt of your application, first
contact your courier. If you still have a question, contact the PGO-TIM
staff at: 770-488-2700. Before calling, please wait two to three days
after the application deadline. This will allow time for applications
to be processed and logged.
IV.4. Intergovernmental Review of Applications
Executive Order 12372 does not apply to this program.
IV.5. Funding Restrictions
Restrictions, which must be taken into account while writing your
budget, are as follows:
Funds may be used only for activities associated with
decreasing unsafe injections.
Funds may be spent for reasonable program purposes,
including personnel, travel, supplies, and services. Equipment may be
purchased if deemed necessary to accomplish program objectives;
however, prior approval by HHS/CDC officials must be requested in
writing.
All requests for funds contained in the budget shall be
stated in U.S. dollars. Once an award is made, HHS/CDC will not
compensate foreign grantees for currency exchange fluctuations through
the issuance of supplemental awards.
The costs that are generally allowable in grants to
domestic organizations are allowable to foreign institutions and
international organizations, with the following exception: With the
exception of the American University, Beirut, and the World Health
Organization, Indirect Costs will not be paid (either directly or
through sub-award) to organizations located outside the territorial
limits of the United States or to international organizations
regardless of their location.
The applicant may contract with other organizations under
this program; however, the applicant must perform a substantial portion
of the activities (including program management and operations, and
delivery of prevention services for which funds are required).
You must obtain an annual audit of these HHS/CDC funds
(program-specific audit) by a U.S.-based audit firm with international
branches and current licensure/authority in-country, and in accordance
with International Accounting Standards or equivalent standard(s)
approved in writing by HHS/CDC.
A fiscal Recipient Capability Assessment may be required,
prior to or post award, in order to review the applicant's business
management and fiscal capabilities regarding the handling of U.S.
Federal funds.
U.S. Government funds may be used for direct costs such as
salaries; necessary travel; operating costs, including supplies, fuel,
utilities, etc.; staff training costs, including registration fees and
purchase and rental of training related equipment; and purchase of HIV-
testing reagents, test kits, and laboratory equipment for HIV testing.
No funds appropriated under this solicitation shall be
used to carry out any program of distributing sterile needles or
syringes for the hypodermic use of any illegal drug.
In accordance with 45 CFR Part 74.81, no HHS funds may be
paid as profit to any recipient, even if the recipient is a commercial
organization. Profit is any amount in excess of allowable direct and
indirect costs.
The U.S. Government is opposed to prostitution and related
activities, which are inherently harmful and dehumanizing, and
contribute to the phenomenon of trafficking in persons. Any entity that
receives, directly or indirectly, U.S. Government funds in connection
with this document (``recipient'') cannot use such U.S. Government
funds to promote or advocate the legalization or practice of
prostitution or sex trafficking. Nothing in the preceding sentence
shall be construed to preclude the provision to individuals of
palliative care, treatment, or post-exposure pharmaceutical
prophylaxis, and necessary pharmaceuticals and commodities, including
test kits, condoms, and, when proven effective, microbicides. A
recipient that is otherwise eligible to receive funds in connection
with this document to prevent, treat, or monitor HIV/AIDS shall not be
required to endorse or utilize a multisectoral approach to combating
HIV/AIDS, or to endorse, utilize, or participate in a prevention method
or treatment program to which the recipient has a religious or moral
objection. Any information provided by recipients about the use of
condoms as part of projects or activities that are funded in connection
with this document shall be medically accurate and shall include the
public health benefits and failure rates of such use.
In addition, any foreign recipient must have a policy explicitly
opposing, in its activities outside the United States, prostitution and
sex trafficking, except that this requirement shall not apply to the
Global Fund to Fight AIDS, Tuberculosis and Malaria, the World Health
Organization, the International AIDS Vaccine Initiative or to any
United Nations agency, if such entity is a recipient of U.S. Government
funds in connection with this document.
The following definitions apply for purposes of this clause:
``Sex trafficking'' means the recruitment, harboring,
transportation, provision, or obtaining of a person for the purpose of
a commercial sex act. 22 U.S.C. 7102(9).
A ``foreign recipient'' includes an entity that is not
organized under the laws of any State of the United States, the
District of Columbia, or the Commonwealth of Puerto Rico. Restoration
of the Mexico City Policy, 66 FR 17303, 17303 (March 28, 2001).
All recipients must insert provisions implementing the applicable
parts of this section, ``Prostitution and Related Activities,'' in all
subagreements under this award. These provisions must be express terms
and conditions of the subagreement, acknowledge that each certification
to compliance with this section, ``Prostitution and Related
Activities,'' are a prerequisite to receipt of U.S. government funds in
connection with this document, and must acknowledge that any violation
of the provisions shall be grounds for unilateral termination of the
agreement prior to the end of its term. In addition, all recipients
must ensure, through contract, certification, audit, and/or any other
necessary means, all the applicable requirements in this section,
``Prostitution and Related Activities,'' are met by any other entities
receiving U.S. government funds from the recipient in connection with
this document, including without limitation, the recipients' sub-
grantees, sub-contractors, parents, subsidiaries, and affiliates.
Recipients must agree that HHS may, at any reasonable time, inspect the
documents and materials maintained or prepared by the recipient in the
usual course of its operations that relate to the organization's
compliance with this section, ``Prostitution and Related Activities.''
All primary grantees that receive U.S. Government funds in
connection with this document must certify compliance prior to actual
receipt of such funds in a written statement referencing this document
(e.g., ``[Recipient's name]
[[Page 42182]]
certifies compliance with the section, `Prostitution and Related
Activities.' '') addressed to the agency's grants officer. Such
certifications are prerequisites to the payment of any U.S. Government
funds in connection with this document.
Recipients' compliance with this section, ``Prostitution and
Related Activities,'' is an express term and condition of receiving
U.S. Government funds in connection with this document, and any
violation of it shall be grounds for unilateral termination by HHS of
the agreement with HHS in connection with this document prior to the
end of its term. The recipient shall refund to HHS the entire amount
furnished in connection with this document in the event it is
determined by HHS that the recipient has not complied with this
section, ``Prostitution and Related Activities.''
Guidance for completing your budget can be found on the HHS/CDC Web
site, at the following Internet address: http://www.cdc.gov/od/pgo/funding/budgetguide.htm
.
Applicants should budget for activities in all seven countries. The
final determination of funding and country assignment will be
determined at the time of award.
IV.6. Other Submission Requirements
Application Submission Address: Submit the original and two hard
copies of your application by mail or express delivery service to:
Technical Information Management-PA 04212, CDC Procurement and
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341.
Applications may not be submitted electronically at this time.
V. Application Review Information
V.1. Criteria
You are required to provide measures of effectiveness that will
demonstrate the accomplishment of the various identified objectives of
the cooperative agreement. Measures of effectiveness must relate to the
performance goals stated in the ``Purpose'' section of this
announcement. Measures must be objective and quantitative, and must
measure the intended outcome. These measures of effectiveness must be
submitted with the application and will be an element of evaluation.
Your application will be evaluated against the following criteria:
1. Current Capability (Total: 45 Points)
a. Experience in the area of safe injections (15 points)--Does the
applicant and each of its partnering organizations have experience
working in the area of medical injection safety in developing
countries?
b. Experience in the area of infection-control practices (15
points)--Does the applicant and each of its partnering organizations
have experience working in the area of infection control practices in
developing countries?
c. Staffing and management (15 points)--Is the size of the
organization adequate for the project? Is the current staffing and
management capacity of the applicant adequate for the project?
2. Feasibility of Plan (Total: 40 Points)
a. Technical approach (6 points)--Is the technical approach sound
and reasonable?
b. Staffing and management (8 points)--Is the proposed staffing and
management plan reasonable?
c. Equipment and supplies management and distribution (8 points)--
Does the applicant have a sound and reasonable plan for managing and
distributing safe injectable materials and supplies?
d. Training (6 points)--Does the applicant have the resources and a
reasonable plan to develop a comprehensive training program in the
reduction of unsafe medical injections and in infection control
practices?
e. Monitoring and evaluation (6 points)--Is the monitoring and
evaluation plan feasible? Does the plan measure important indicators?
f. Sustainability (6 points)--Is the plan for sustainability
reasonable and feasible?
3. Measures of Effectiveness (Total: 10 Points)
Are the measures of effectiveness reasonable?
4. Plans for Collaboration (Total: 5 Points)
Is there a plan or strategy for effectively collaborating with the
Ministries of Health and local health-care providers?
V.2. Review and Selection Process
The Procurement and Grants Office (PGO) staff will review your
application for completeness, and the HHS/CDC National Center for HIV,
STD and TB Prevention (NCHSTP) will review it for responsiveness.
Incomplete applications and applications that are non-responsive to the
eligibility criteria will not advance through the review process.
Applicants will be notified that their application did not meet
submission requirements.
An objective review panel will evaluate complete and responsive
applications according to the criteria listed in the ``V.1. Criteria''
section above.
In addition, the following factors may affect the funding decision:
Geographic distribution and population of all seven
countries--to ensure that funding is not concentrated in any one
catchment area.
Percentage of staff who are citizens of the country in
which services will be provided.
No award will be made without the concurrence of the U.S.
Embassy and the CDC representative in the country under consideration.
V.3. Anticipated Announcement and Award Dates
September 1, 2004.
VI. Award Administration Information
VI.1. Award Notices
Successful applicants will receive a Notice of Grant Award (NGA)
from the HHS/CDC Procurement and Grants Office. The NGA shall be the
only binding, authorizing document between the recipient and HHS/CDC.
The NGA will be signed by an authorized Grants Management Officer, and
mailed to the recipient fiscal officer identified in the application.
Unsuccessful applicants will receive notification of the results of
the application review by mail.
VI.2. Administrative and National Policy Requirements
45 CFR Part 74 and Part 92
For more information on the Code of Federal Regulations, see the
National Archives and Records Administration at the following Internet
address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements apply to this project:
AR-4 HIV/AIDS Confidentiality Provisions
AR-5 HIV Program Review Panel Requirements
AR-6 Patient Care
AR-9 Paperwork Reduction Act Requirements
AR-10 Smoke-Free Workplace Requirements
AR-12 Lobbying Restrictions
AR-15 Proof of Non-Profit Status
AR-16 Security Clearance Requirement
AR-23 States and Faith-Based Organizations
Additional information on these requirements can be found on the
HHS/CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm
.
[[Page 42183]]
VI.3. Reporting Requirements
You must provide HHS/CDC with an original, plus two copies of the
following reports:
1. Interim progress report, no less than 90 days before the end of
the budget period. The progress report will serve as your non-competing
continuation application, and must contain the following elements:
a. Current Budget Period Activities Objectives.
b. Current Budget Period Financial Progress.
c. New Budget Period Program Proposed Activity Objectives.
d. Detailed Line-Item Budget and Justification.
e. Additional Requested Information.
f. Measures of Effectiveness.
2. Semi-annual progress report, due seven months after the
beginning of each budget period. This report should contain the
following elements:
a. Progress on Achieving Objectives.
b. Modification or New Activities.
3. Financial status report, no more than 90 days after the end of
the budget period.
4. Final financial and performance reports, no more than 90 days
after the end of the project period.
These reports must be sent to the Grants Management Specialist
listed in the ``Agency Contacts'' section of this announcement.
VII. Agency Contacts
For general questions about this announcement, contact:
Technical Information Management Section, HHS/CDC Procurement and
Grants Office, Centers for Disease Control and Prevention, U.S.
Department of Health and Human Services, 2920 Brandywine Road, Atlanta,
GA 30341, Telephone: 770-488-2700.
For program technical assistance, contact:
Kenneth Clark, M.D., MPH, Project Officer, National Center for HIV,
STD, and TB Prevention, Centers for Disease Control and Prevention,
U.S. Department of Health and Human Services, 1600 Clifton Road, NE, MS
E04, Atlanta, GA 30333, Telephone: 404-639-8057, E-mail: kjc4@cdc.gov.
For budget assistance, contact:
Diane Flournoy, Contract Specialist, HHS/CDC Procurement and Grants
Office, U.S. Department of Health and Human Services, 2920 Brandywine
Road, Atlanta, GA 30341, Telephone: 770-488-2072, E-mail: dmf6@cdc.gov.
Dated: July 8, 2004.
William P. Nichols,
Acting Director, Procurement and Grants Office, Centers for Disease
Control and Prevention, U.S. Department of Health and Human Services.
[FR Doc. 04-15913 Filed 7-13-04; 8:45 am]
BILLING CODE 4163-18-P